Publications

1. Glycerol phenylbutyrate (Ravicti®) for the treatment of urea-cycle disorders

   The National Health Care Institute has carried out an assessment of the medicinal product glycerol phenylbutyrate (Ravicti®) for ...

   Report | 12-09-2017

2. Zinnige Zorg room for improvement report - In-depth phase neoplasms: care during the final stage of life of patients with incurable intestinal or lung cancer

   The final stage of life is one in which a patient is of an advanced age or has a disease and/or is in a phase of a disease that ...

   Report | 01-09-2017

3. Cetuximab (Erbitux®) for the treatment of metastatic colorectal cancer

   The National Health Care Institute has carried out a re-assessment of the medicinal product cetuximab (Erbitux®), whereby they ...

   Report | 26-06-2017

4. Acarizax® in cases of allergic rhinitis due to house dust mite

   The National Health Care Institute carried out an assessment of whether the medicinal product Acarizax® is interchangeable with a ...

   Report | 26-06-2017

5. A paradigm shift in perception, learning and action - core of the second advice of the Committee Innovation Health Care Professions & Education

   Translation of the core of the second advice of The Committee Innovation Health Care Professions & Education. This report is a ...

   Report | 18-05-2017

6. Tenofovir alafenamide (Vemlidy®) for the treatment of chronic hepatitis B infection

   The National Health Care Institute carried out an assessment of the medicine tenofovir alafenamide (Vemlidy®). Based on the ...

   Report | 26-04-2017

7. Migalastat (Galafold®) for the treatment of Fabry's disease

   The National Health Care Institute carried out an assessment of whether, based on the criteria of the Medicines Reimbursement ...

   Report | 25-04-2017

8. Elosulfase alfa (Vimizim®) for the treatment of Morquio A syndrome

   The National Health Care Institute carried out a reassessment of the medicinal product elosulfase alfa (Vimizim®). This report is ...

   Report | 24-04-2017

9. Ibrutinib (Imbruvica®) for the treatment of chronic lymphatic leukaemia

   The National Health Care Institute carried out an assessment of the medicinal product ibrutinib (Imbruvica®), for the first-line ...

   Report | 24-04-2017

10. Cysteamine with delayed release (Procysbi®)

    The National Health Care Institute Institute carried out an assessment of the medicine cysteamine with delayed release ...

    Report | 23-03-2017